Search research articles
Contact Us
Filters
Showing results (391-400 of 438) with videos related to
Page
of 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Philip Bischoff, Martin Reck, Tobias Overbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
The New England Journal of Medicine
|
June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer, Karen L Reckamp, Paul Baas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 29, 2021
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
Tetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2023
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Byoung Chul Cho, Jong Seok Lee, Yi-Long Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Page
of 44
Search research articles
Search
Showing results (391-400 of 438) with videos related to
Sort By:
Page
of 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Philip Bischoff, Martin Reck, Tobias Overbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
The New England Journal of Medicine
|
June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer, Karen L Reckamp, Paul Baas, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 29, 2021
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC
Tetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
The New England Journal of Medicine
|
October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
John V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2023
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Byoung Chul Cho, Jong Seok Lee, Yi-Long Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Page
of 44